The potential role of purine-rich element binding protein (PUR) α as a novel treatment target for hormone-refractory prostate cancer

Prostate

Volumn 68, Issue 10, 2008, Pages 1048-1056

  Inoue, Takahiro ^a   Leman, Eddy S ^a   Yeater, David B ^a   Getzenberg, Robert H ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Hormone refractory prostate cancer; Purine rich element binding protein ; Treatment target

Indexed keywords

ANDROGEN; BINDING PROTEIN; MESSENGER RNA; NUCLEAR MATRIX PROTEIN; PURINE RICH ELEMENT BINDING PROTEIN ALPHA;

ARTICLE; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CELL GROWTH; CELL NUCLEUS MATRIX; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; CULTURE MEDIUM; DRUG TARGETING; HUMAN; HUMAN CELL; MASS SPECTROMETRY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TWO DIMENSIONAL ELECTROPHORESIS;

CELL DIVISION; CELL LINE, TUMOR; DNA-BINDING PROTEINS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HORMONES; HUMANS; MALE; MUTAGENESIS; NUCLEAR MATRIX; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSCRIPTION FACTORS;

EID: 45749106356     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20764     Document Type: Article

References (32)

1. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-39.
2. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
3. Zink D, Fischer AH, Nickerson JA. Nuclear structure in cancer cells. Nat Rev Cancer 2004;9:677-687.
4. Konety BR, Getzenberg RH. Nuclear structural proteins as biomarkers of cancer. J Cell Biochem 1999;32 (Suppl 32-33):183-191.
5. Berezney R, Coffey DS. Nuclear matrix. Isolation and characterization of a framework structure from rat liver nuclei. J Cell Biol 1977;73:616-616.
6. Capco DG, Wan KM, Penman S. The nuclear matrix: Three-dimensional architecture and protein composition. Cell 1982;29:847-858.
7. Getzenberg RH, Konety BR, Oeler TA, Quigley MM, Hakam A, Becich MJ, Bahnson RR. Bladder cancer-associated nuclear matrix proteins. Cancer Res 1996;56:1690-1694.
8. Partin AW, Getzenberg RH, CarMichael MJ, Vindivich D, Yoo J, Epstein JI, Coffey DS. Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res 1993;53:744-746.
9. Brünagel G, Vietmeier BN, Bauer AJ, Schoen RE, Getzenberg RH. Identification of nuclear matrix protein alterations associated with human colon cancer. Cancer Res 2002;62:2437-2442.
10. Konety BR, Nguyen TS, Dhir R, Day RS, Becich MJ, Stadler WM, Getzenberg RH. Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin Cancer Res 2000;6:2618-2625.
11. Leman ES, Cannon GW, Trock BJ, Sokoll LJ, Chan DW, Mangold L, Partin AW, Getzenberg RH. EPCA-2: A highly specific serum marker for prostate cancer. Urology 2007;69:714-720.
12. Leman ES, Schoen RE, Weissfeld JL, Cannon GW, Sokoll LJ, Chan DW, Getzenberg RH. Initial analyses of colon cancer-specific antigen (CCSA)-3 ard CCSA-4 as colorectal cancer-associated serum markers. Cancer Res 2007;67:5600-5605.
13. Bergemann AD, Johnson EM. The HeLa Pur factor binds single-stranded DNA at a specific element conserved in gene flanking regions and origins of DNA replication. Mol Cell Biol 1992;12:1257-1265.
14. Bergemann AD, Ma ZW, Johnson EM. Sequence of cDNA comprising the human pur gene and sequence-specific single-stranded-DNA-binding properties of the encoded protein. Mol Cell Biol 1992;12:5673-5682.
15. Gallia GL, Johnson EM, Khalili K. Puralpha: A multifunctional single-stranded DNA- and RNA-binding protein. Nucleic Acids Res 2000;28:3197-3205.
16. Chang CF, Gallia GL, Muralidharan V, Chen NN, Zoltick P, Johnson E, Khalili K. Evidence that replication of human neurotropic JC virus DNA in glial cells is regulated by the sequence-specific single-stranded DNA-binding protein Pur alpha. J Virol 1996;70:4150-4156.
17. Itoh H, Wortman MJ, Kanovsky M, Uson RR, Gordon RE, Alfano N, Johnson EM. Alterations in Pur(alpha) levels and intracellular localization in the CV-1 cell cycle. Cell Growth Differ 1998;9:651-665.
18. Liu H, Barr SM, Chu C, Kohtz DS, Kinoshita Y, Johnson EM. Functional interaction of Puralpha with the Cdk2 moiety of cyclin A/Cdk. Biochem Biophys Res Commun 2005;328:851-857.
19. Johnson EM, Chen PL, Krachmarov CP, Barr SM, Kanovsky M, Ma ZW, Lee WH. Association of human Pur alpha with the retinoblastoma protein, Rb, regulates binding to the single-stranded DNA Pur alpha recognition element. J Biol Chem 1995;270:24352-24360.
20. Darbinian N, Gallia GL, Kundu M, Shcherbik N, Tretiakova A, Giordano A, Khalili K. Association of Pur alpha and E2F-1 suppresses transcriptional activity of E2F-1. Oncogene 1999;18:6398-6402.
21. Yeh S, Miyamoto H, Nishimura K, Kang H, Ludlow J, Hsiao P, Wang C, Su C, Chang C. Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells. Biochem Biophys Res Commun 1998;248:361-367.
22. Davis JN, Wojno KJ, Daignault S, Hofer MD, Kuefer R, Rubin MA, Day ML. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. Cancer Res 2006;66:11897-11906.
23. Inoue T, Yoshida T, Shimizu Y, Kobayashi T, Yamasaki T, Toda Y, Segawa T, Kamoto T, Nakamura E, Ogawa O. Requirement of androgen-dependent activation of protein kinase Czeta for androgen-dependent cell proliferation in LNCaP cells and its roles in transition to androgen-independent cells. Mol Endocrinol 2006;20:3053-3069.
24. Pflug BR, Reiter RE, Nelson JB. Caveolin expression is decreased following androgen deprivation in human prostate cancer cell lines. Prostate 1999;40:269-273.
25. Inoue T, Nakanishi H, Inada K, Hioki T, Tatematsu M, Sugimura Y. Real time reverse transcriptase polymerase chain reaction of urinary cytokeratin 20 detects transitional cell carcinoma cells. J Urol 2001;166:2134-2141.
26. Fey EG, Wan KM, Penman S. Epithelial cytoskeletal framework and nuclear matrix-intermediate filament scaffold: Three-dimensional organization and protein composition. J Cell Biol 1984;98:1973-1984.
27. Hardy E, Castellanos-Serra LR. "Reverse-staining" of biomolecules in electrophoresis gels: Analytical and micropreparative applications. Anal Biochem 2004;328:1-13.
28. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins from silver-stained Polyacrylamide gels. Anal Chem 1996;68:850-858.
29. Getzenberg RH, Coffey DS. Tissue specificity of the hormonal response in sex accessory tissues is associated with nuclear matrix protein patterns. Mol Endocrinol 1990;4:1336-1342.
30. Stacey DW, Hitomi M, Kanovsky M, Gan L, Johnson EM. Cell cycle arrest and morphological alterations following microinjection of NIH3T3 cells with Pur alpha. Oncogene 1999;18:4254-4261.
31. Barr SM, Johnson EM. Ras-induced colony formation and anchorage-independent growth inhibited by elevated expression of Puralpha in NIH3T3 cells. J Cell Biochem 2001;81:621-638.
32. Darbinian N, Gallia GL, King J, Del Valle L, Johnson EM, Khalili K. Growth inhibition of glioblastoma cells by human Pur(alpha). J Cell Physiol 2001;189:334-340.